Phio gets SMC nod to advance PH-762 skin cancer trial to 4th dose cohort

Phio Pharmaceuticals Corp.

Safety Monitoring Committee recommended dose escalation to fourth cohort in Phase 1b trial (NCT06014086).
Third cohort (3 patients with cutaneous squamous cell carcinoma): no serious AEs, no dose-limiting toxicities.
Prior second cohort (4 patients): 2 complete responses (100% tumor clearance), 1 partial (90% clearance) at Day 36.
PH-762 is an intratumoral siRNA compound targeting cutaneous SCC, melanoma, and Merkel cell carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.